.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
AstraZeneca
QuintilesIMS
UBS
Chinese Patent Office
Express Scripts
Argus Health
Julphar
Fuji
Colorcon

Generated: June 25, 2017

DrugPatentWatch Database Preview

STENDRA Drug Profile

« Back to Dashboard

What is the patent landscape for Stendra, and when can generic versions of Stendra launch?

Stendra is a drug marketed by Metuchen Pharms and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-two patent family members in twenty-six countries.

The generic ingredient in STENDRA is avanafil. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the avanafil profile page.

Summary for Tradename: STENDRA

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list38
Clinical Trials: see list6
Patent Applications: see list529
Drug Prices:see details
DailyMed Link:STENDRA at DailyMed

Pharmacology for Tradename: STENDRA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Metuchen Pharms
STENDRA
avanafil
TABLET;ORAL202276-001Apr 27, 2012RXYesNo7,501,409► SubscribeY ► Subscribe
Metuchen Pharms
STENDRA
avanafil
TABLET;ORAL202276-002Apr 27, 2012RXYesNo► Subscribe► Subscribe
Metuchen Pharms
STENDRA
avanafil
TABLET;ORAL202276-001Apr 27, 2012RXYesNo► Subscribe► Subscribe
Metuchen Pharms
STENDRA
avanafil
TABLET;ORAL202276-003Apr 27, 2012RXYesYes► Subscribe► Subscribe
Metuchen Pharms
STENDRA
avanafil
TABLET;ORAL202276-002Apr 27, 2012RXYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: STENDRA

Drugname Dosage Strength RLD Submissiondate
avanafilTablets50 mg, 100 mg and 200 mgStendra4/27/2016

Non-Orange Book Patents for Tradename: STENDRA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,797,709 Aromatic nitrogen-containing 6-membered cyclic compounds► Subscribe
7,273,868Pyrazine derivatives► Subscribe
7,220,736Pyrimidine compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: STENDRA

Country Document Number Estimated Expiration
Australia2001284444► Subscribe
TaiwanI258471► Subscribe
Australia767558► Subscribe
Denmark1219609► Subscribe
China1374953► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: STENDRA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2013 00040Denmark► Subscribe
90047-7Sweden► SubscribePRODUCT NAME: AVANAFIL; REG. NO/DATE: EU/1/13/841 20130621
00618Netherlands► SubscribePRODUCT NAME: AVANAFIL; REGISTRATION NO/DATE: EU/1/13/841 20130621
C0050France► SubscribePRODUCT NAME: AVANAFIL; REGISTRATION NO/DATE: EU/1/13/841 20130621
249Luxembourg► SubscribePRODUCT NAME: AVANAFIL
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Argus Health
QuintilesIMS
Colorcon
McKesson
Cerilliant
UBS
Express Scripts
Accenture
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot